DSM-Firmenich Q1 2024 Shows Robust Growth In Key Segments Amidst Challenges

In the first quarter of 2024, Swiss-Dutch conglomerate dsm-firmenich showcased a robust performance, particularly in its Perfumery & Beauty and Taste, Texture & Health divisions, attributed to heightened demand and volume expansion. Despite this, the Health, Nutrition & Care sector experienced a subdued quarter, albeit with a late surge in momentum. The Animal Nutrition & Health division faced challenges, primarily due to the anticipation of rising vitamin prices in the subsequent quarter. Amid these varied performances, dsm-firmenich has initiated the separation process for its Animal Nutrition & Health business and remains steadfast in its operational enhancement and strategic endeavors.

The company's financial outlook for the fiscal year 2024 remains steady, projecting an Adjusted EBITDA of at least €1.9 billion. This forecast includes a significant contribution from synergy realization and the ongoing vitamin transformation program. In the first quarter of 2024, dsm-firmenich recorded sales totaling €3.1 billion, marking a slight 2% decline from the pro forma figures of Q1 2023. Despite this dip, organic sales growth remained stable. The Adjusted EBITDA for this period was €463 million, experiencing an 11% decrease compared to the same period in the previous year.

The Perfumery & Beauty segment witnessed a modest sales increase of 1%, reaching €986 million, with organic sales growth reported at 2%. This segment's Adjusted EBITDA saw an impressive 11% rise to €234 million. Conversely, the Taste, Texture & Health division enjoyed a 3% sales boost to €798 million and a notable 6% organic sales growth. However, its Adjusted EBITDA slightly declined by 1% to €150 million.

Challenges were more pronounced in the Health, Nutrition & Care segment, which saw a 10% decrease in sales to €526 million and a -9% organic sales growth. The Adjusted EBITDA for this sector plummeted by 34% to €79 million. The Animal Nutrition & Health segment also faced difficulties, with sales falling by 5% to €746 million and organic sales decreasing by -3%. Its Adjusted EBITDA drastically reduced by 65% to €24 million.

Dimitri de Vreeze, CEO of dsm-firmenich, expressed satisfaction with the positive market environment and the resurgence of volume growth across key segments. He highlighted the company's continuous progress in operational improvements and strategic initiatives. Despite these advancements, de Vreeze maintained a cautious stance regarding market recovery trends but confirmed that the company's full-year guidance remains unchanged.

Looking ahead, dsm-firmenich is poised to host a Capital Markets Day in Paris on June 3. This event will concentrate on elucidating the company's innovation-led growth strategy. With its Q1 2024 performance reflecting both strengths and areas for improvement, dsm-firmenich is navigating through market uncertainties with a cautious yet optimistic outlook. The firm's commitment to strategic improvements and innovation remains central to its growth trajectory in FY 2024.